


"Express Mail" Label No. EV 332086377 US
Date of Deposit December 16, 2004

PATENT
Attorney Docket No.: 082368-001500US
Client Ref. No.: E1-A0305Y1P-US

I hereby certify that this is being deposited with the United States Postal Service "Express Mail Post Office to Address" service under 37 CFR 1.10 on the date indicated above and is addressed to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

By: 
Aaron Hokamura

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

ITO and SAITO

Application No.: Not yet assigned

Filed:

U.S. National Phase of:
PCT/JP03/07721

Int'l Filing Date: June 18, 2003

For: PRIMARY CULTURED
ADIPOCYTES FOR GENE THERAPY

Customer No.: 20350

Confirmation No.

Examiner: Not yet assigned

Technology Center/Art Unit: Not yet
assigned

PRELIMINARY AMENDMENT

and

COMMUNICATION UNDER

37 C.F.R. §§ 1.821-1.825

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In order to comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, 37 C.F.R. §§ 1.821-1.825, Applicants submit herewith a Sequence Listing in paper and computer readable forms.

Prior to examination of the above-referenced application, please enter the following amendments and remarks:

Amendments to the Specification begin on page 3 of this paper.

Appl. No.

PATENT

Amdt. dated December 16, 2004

Preliminary Amendment

Amendments to the Claims are reflected in the listing of claims which begins on page 9 of this paper.

Remarks/Arguments begin on page 11 of this paper.